GET DAILY SIGNALSSenseonics Holdings (SENS): Weighing the Path to a $13 Price Target
Key Takeaways
- The central $13 stock price target is the arithmetic mean of six verified analyst price targets, rounded from roughly $13.33; the range spans $10 to $18.
- With shares around $9.80 as of early November 2026, reaching $13 would require a roughly 33% advance — a substantial move, not a trivial one.
- Sentiment is split: several Buy ratings (H.C. Wainwright, TD Cowen, Lake Street, Mizuho) sit alongside Hold ratings from Barclays and Stifel, and the wide target range reflects genuine disagreement about execution risk.
- The strongest supports are accelerating revenue from the Eversense 365 implantable continuous glucose monitor, rising guidance, and improving gross margins.
- The biggest risks are the costly in-house commercialization transition, ongoing losses, potential dilution, and competition from much larger diabetes-technology players.
- For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
- You can also explore Trending AI Robots for automated, AI-driven trading strategies across the market.
Analyst Price Targets and the Consensus View
Senseonics Holdings, Inc. (SENS) develops and sells the Eversense family of long-term, implantable continuous glucose monitoring systems for diabetes patients. As an early-stage company still posting losses, it draws a limited but divided group of analysts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The six current price targets break down as $10 (Stifel, Hold), $11 (Barclays, Equal Weight), $12 (Lake Street, Buy), $14 (H.C. Wainwright, Buy), $15 (TD Cowen, Buy), and $18 (Mizuho, Outperform). Their arithmetic mean comes to about $13.33, which rounds to the $13 central target referenced here. This is a calculated average rather than an official consensus, and the $10-to-$18 spread stands out as unusually wide.
The split does not stem from doubts about the technology itself. Most analysts recognize that Eversense 365, with its year-long sensor life, offers a meaningful edge and is gaining users. The real differences arise from how each firm weighs the risks around commercial execution and future share issuance as the company shifts to in-house sales and distribution while funding its pipeline.
Current Market Position and the Route to the Target
Shares closed near $9.80 on November 9, 2026, following a post-earnings rally that extended into after-hours trading around the $10.40–$10.60 zone. Closing the gap to the $13 target from that level would require an advance of roughly 33%, a move that qualifies as substantial for this name.
Third-quarter 2026 revenue reached about $19.6 million, up approximately 140% from a year earlier. Management raised full-year 2026 revenue guidance to $68–$70 million and lifted its gross-margin outlook above 60%. The company remains unprofitable on a GAAP basis, so progress toward the target hinges more on sustained revenue growth and margin expansion than on near-term earnings.
Supports That Could Push Shares Higher
- Accelerating revenue growth driven by Eversense 365 adoption and a rapidly expanding patient base, with new-user growth weighted toward Type 2 diabetes.
- Raised guidance and margin trajectory, with management guiding to revenue of $68–$70 million and gross margins above 60% for 2026.
- Pipeline optionality, including the Gemini platform and the Freedom sensor, which analysts view as the form factor that could matter most for physicians and patients.
- Greater market visibility from an upgraded Nasdaq listing, index inclusion, and growing institutional ownership.
Risks That Could Keep the Target Out of Reach
- Commercial execution risk as the company internalizes sales and distribution previously handled by its partner, a transition several analysts flag as requiring additional capital.
- Persistent losses and dilution risk, including a completed public offering and an earlier 1-for-20 reverse stock split that reflect balance-sheet pressure.
- Intense competition from far larger rivals such as DexCom (DXCM) and Abbott Laboratories (ABT), whose scale in CGM could limit share gains.
- Single-product concentration, which leaves the company exposed to reimbursement changes and potential technological disruption.
Technical Levels and Market Structure
The shares recently traded near the top of a wide 52-week range of roughly $4.79 to $10.64. A decisive move above the $10.64 prior high would serve as a meaningful breakout signal. The $10 level now acts as psychological and near-term resistance that has just been tested. The $13 target sits in open territory above the recent 50-day moving average (around $9.18) and the 200-day moving average (around $7.22), indicating the medium-term trend has been constructive even before the latest rally. A pullback below the $8.50–$9.00 area would signal a loss of the recently reclaimed ground.
Time Horizon and Key Items to Monitor
Analyst targets generally reflect a roughly 12-month horizon, though some were set before the latest results. Investors should track upcoming quarterly revenue and patient-growth figures, any further guidance updates, gross-margin trends, revisions to analyst targets after the recent report, and additional capital raises. Reimbursement decisions and the timing of the Freedom sensor launch in the back half of 2027 represent longer-term but important variables.
AI Daily Buy/Sell Signals
In my own work I frequently review Tickeron’s AI Daily Buy/Sell Signals to stay on top of technical shifts in names like this one. The system applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving market conditions and price behavior. It does not replace analysis but helps surface opportunities and trend changes more quickly than manual review alone. For event-driven stocks such as Senseonics, pairing fundamental research with these continuously updated signals provides helpful additional context.
Final Assessment
Can Senseonics Holdings (SENS) reach $13? The question centers on execution rather than product innovation. The $13 figure represents a calculated average of six analyst targets ranging from $10 to $18, pointing to roughly 33% upside from the recent price near $9.80 — a notable but plausible move for a small-cap growth stock that just posted a strong quarter and raised guidance. The bull case rests on Eversense 365 momentum, margin expansion, and pipeline differentiation. The bear case centers on the costs of bringing commercialization in-house, ongoing losses, dilution risk, and competition from much larger players. With ratings split between Hold and Buy and a target range nearly as wide as the stock price itself, $13 is best viewed as a midpoint reflecting divided opinion rather than a level the market is assured of hitting.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SENS's RSI Indicator ascends from oversold territory
The RSI Indicator for SENS moved out of oversold territory on October 23, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 46 similar instances when the indicator left oversold territory. In 43 of the 46 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on SENS as a result. In 70 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for SENS just turned positive on October 28, 2026. Looking at past instances where SENS's MACD turned positive, the stock continued to rise in 36 of 40 cases over the following month. The odds of a continued upward trend are 90%.
SENS moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SENS crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +16.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where SENS advanced for three days, in 197 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 52 cases where SENS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SENS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
SENS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SENS entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. SENS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.029) is normal, around the industry mean (4.142). P/E Ratio (-3.835) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (9.058) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SENS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative glucose monitoring products
Industry MedicalNursingServices
Advertisement